Weight Loss Injections and Rheumatoid Arthritis: What to Consider

Step 1: understanding why body weight matters specifically in rheumatoid arthritis

Rheumatoid arthritis is driven by systemic inflammation, and adipose tissue (particularly visceral fat) is not metabolically inert. It produces pro-inflammatory cytokines including tumour necrosis factor-alpha and interleukin-6, some of the same pathways targeted by biologics. For people living with RA, higher body weight can make disease control harder and may blunt the response to certain treatments. The joints of the knees, hips and feet also carry extra mechanical load, which matters even though RA is not primarily a load-bearing disease.

The NHS notes on its tirzepatide medicines page that the medicine is licensed for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition. Rheumatoid arthritis sits within that second group, meaning a BMI below 30 does not automatically disqualify someone with active or established RA. That said, a prescriber will look at disease activity, current medications and overall clinical picture, not just the number on the scales. Suitability is never assumed from BMI alone.

There is also early-stage research interest in whether GLP-1 receptor agonists have independent anti-inflammatory effects beyond weight reduction. This is not an established licensed claim, and it should not drive a decision to start treatment; it simply means the academic picture is developing. Our prescribers discuss what is known and what remains uncertain at the point of consultation. You can read more about inflammatory conditions and weight loss injections if you are managing more than one such diagnosis.

Step 2: reviewing your current RA medications before starting a GLP-1

This is where careful prescriber review becomes non-negotiable. Several medicines routinely used in RA need thinking through alongside a GLP-1.

Methotrexate is usually taken once a week as a tablet, and its absorption depends on gastric transit. GLP-1 medicines slow gastric emptying (that is part of how they reduce appetite) and slowing the stomach's clearance rate can theoretically alter the absorption of orally taken drugs. The clinical significance for methotrexate specifically is not yet fully quantified, but it is a known mechanism your prescriber needs to weigh up. Hydroxychloroquine, leflunomide and the JAK inhibitors (baricitinib, upadacitinib, tofacitinib) are also oral agents where the same principle applies.

Biologics given by injection (adalimumab, etanercept, tocilizumab and others) are delivered subcutaneously or intravenously, so the gastric-emptying question does not apply in the same way. However, some biologics carry their own metabolic effects (tocilizumab, for instance, can raise lipid levels), and a prescriber will consider the full interaction landscape. Corticosteroids, which many RA patients take as bridging therapy, can work against weight management efforts, that is worth discussing too.

The BNF entry for tirzepatide lists the known interactions and cautions; your prescriber cross-references this alongside your medication list during the consultation. The answer you get is specific to you, not a category.

Step 3: what a nume consultation looks like when you have rheumatoid arthritis

When you submit a consultation, a GPhC-registered Independent Prescriber reads your answers the same day. For someone managing RA, that means the prescriber looks at which disease-modifying drugs you take, what dose and frequency, how stable your condition is, and whether your rheumatologist has offered any guidance about weight management. You are not filtered by a form algorithm; a named clinician makes the call.

Practically, the prescription fee, consultation, and delivery are all included in one price, there are no separate consultation fees layered on top. If you're curious about how costs compare, the weight loss injections cost page sets out the full picture. nume dispatches orders placed by 12pm on a working day the same day, via DPD, in plain packaging, useful to know if you are already managing a weekly injection routine around your RA treatment schedule.

If your GP is prescribing or monitoring your RA, nume's prescriber will notify them in line with GPhC guidance, so your care is joined up. That GP letter matters more, not less, when your health picture is complex. If you have a separate condition such as a thyroid disorder or MS alongside your RA, our pages on how weight loss injections interact with thyroid conditions and what people with MS should know about weight loss injections may also be relevant to your consultation. If a prescriber decides this is not the right time, they will say so plainly and explain why. Our clinical approach and the team behind it are described on the about page if you want to understand who is making these decisions.

When to get medical help and what to watch for on treatment

If you start a GLP-1 medicine alongside RA medications, a few things are worth knowing. Nausea, vomiting and reduced appetite are common in the first weeks; if these are severe enough to affect your ability to take oral RA drugs at their usual time, contact a prescriber or your GP, do not simply skip your methotrexate dose without guidance. Severe, persistent abdominal pain that radiates to the back should prompt urgent medical attention, as it can signal acute pancreatitis; the MHRA issued a Drug Safety Update in January 2026 specifically highlighting this risk across GLP-1 medicines. You can read more about that on our GLP-1 medicines and pancreatitis page.

Dehydration from gastrointestinal side effects is worth taking seriously if you are on methotrexate, which itself carries a small renal excretion consideration. Keep fluid intake up, and tell your prescriber or rheumatology team if side effects are significant. Side effects can be reported to the MHRA via the Yellow Card scheme, and doing so helps build the evidence base for patients with complex conditions like RA. Our FAQs cover the questions we hear most often about managing treatment alongside existing conditions.